Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER Meeting Abstract


Authors: Baselga, J.; Dent, S. F.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Verma, S.; Wilson, T. R.; Jin, H.; Wang, L.; Schimmoller, F.; Hsu, J. Y.; He, J.; DeLaurentiis, M.; Drullinsky, P.; Jacot, W.
Abstract Title: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
Meeting Title: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 18 Suppl.
Meeting Dates: 2018 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-06-20
Language: English
ACCESSION: WOS:000443284700006
PROVIDER: wos
DOI: 10.1200/JCO.2018.36.18_suppl.LBA1006
Notes: Meeting Abstract: LBA1006 -- Source: Wos
Altmetric Score
MSK Authors
  1. Jose T Baselga
    383 Baselga